Clinical Trial Update: IC14 Antibodies to Treat Individuals With Acute Lung Injury [Phase 2]

View source ↗

Summary

Phase 2 trial of IC14 antibodies for acute lung injury in adults was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• IC14

Snippet

Sponsor: University of Washington | Conditions: Respiratory Distress Syndrome, Adult, Lung Diseases | Phase 2 | Status: TERMINATED